Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 446 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Rallybio Holdings LLC | RLYB | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.58 | 04:44:11 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.58 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 7 | 446 | - | 1.225 - 9.14 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 05:13:27 | 4 | US$ 1.57 | USD |
Rallybio Holdings LLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 59.74M | 37.81M | - | 0 | -74.56M | -1.97 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Rallybio News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RLYB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.68 | 1.73 | 1.56 | 1.62 | 140,565 | -0.10 | -5.95% |
| 1 Month | 1.92 | 2.00 | 1.56 | 1.77 | 206,365 | -0.34 | -17.71% |
| 3 Months | 1.85 | 3.46 | 1.455 | 2.77 | 1,688,615 | -0.27 | -14.59% |
| 6 Months | 2.10 | 3.46 | 1.225 | 2.66 | 915,019 | -0.52 | -24.76% |
| 1 Year | 6.27 | 9.14 | 1.225 | 2.90 | 495,334 | -4.69 | -74.80% |
| 3 Years | 14.92 | 25.78 | 1.225 | 4.74 | 232,559 | -13.34 | -89.41% |
| 5 Years | 14.92 | 25.78 | 1.225 | 4.74 | 232,559 | -13.34 | -89.41% |
Rallybio Description
| Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. |
